Company Overview

Company name: Oxford Cannabinoid Technologies
Description: Developer of cannabinoid based compounds and therapies created to provide more evidence for the effects of cannabinoids in a number of diseases. The company’s novel cannabinoid-based therapies have range of potential medical applications including Inflammatory Disease, Oncology,Neurological Disorders, Pain Management,
enabling doctors to get cannabinoid-based medication for improving the quality of life for millions of patients.
Year founded: 2017
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
City: London
State: England
Country: United Kingdom
Region: Europe

Financial Highlights

Start up capital raised (USD Million): 22.97
Business status: Product Development
Ownership: Privately Held (backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Enterprise value:
Earnings before interest, tax, depreciation and amortization (EBITDA):
Fiscal period:
Financing Status: The company raised GBP 7.6 million of Series A venture funding in a deal led by Imperial Brands and Casa Verde Capital on February 28, 2018. Patrick Stewart, other undisclosed investors and family offices also participated. The capital raised will be used to establish a strategic research partnership and laboratory in Europe. This will support OCT’s research into the mechanisms of cannabinoids in order to develop treatments that improve the quality of life for millions of patients around the world. Previously, the company raised GBP 10 million of venture funding from Kingsley Capital Partners on March 15, 2017. The company will use this funds to identify new medicinal therapies by researching to role of cannabinoids in treatments.
Number of active investors:
Profile last updated: 12-Nov-2018
Last known valuation:
Last known valuation date: